Icosavax
Public CompanyIcosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Life Sciences
- Status
- Public Company
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Nobel Laureate David Baker Secures $7M from Washington Research Foundation for AI-Designed Protein Program at UW
Nobel Laureate David Baker received $7 million from the Washington Research Foundation to advance AI-designed protein research at the University of Washington. The initiative aims to develop designer enzymes for medicine, technology, and sustainability while fostering new scientists and startups.
Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington
David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.
University of Washington’s David Baker Credits Open-Code Rosetta Commons for Protein Design Startup Success
David Baker, director of the University of Washington’s Institute for Protein Design (IPD), emphasizes open code sharing as key to the institute’s success in creating protein design startups. The IPD’s collaborative Rosetta Commons consortium has enabled widespread development of protein design tools, fostering innovation and spinouts in biotech.
People
-
Neil King Co-founder
Questions about Icosavax
What is Icosavax?
Icosavax is a public company based in Seattle that develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19.
What is Icosavax known for?
Icosavax uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
What has Icosavax been in the news for?
GeekWire reported in December 2024 on David Baker’s protein design innovation and startup growth at University of Washington. In March 2024, GeekWire reported that David Baker credited open-code Rosetta Commons for protein design startup success.
Who are the people behind Icosavax?
Neil King is a co-founder of Icosavax.
Who invested in Icosavax, and how much has it raised?
Members of Seattle Flow see Icosavax's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Icosavax based?
Icosavax is based in Seattle.